1
|
Takahashi A, Kitsunai S, Kawana H, Saito N, Yoshihara A, Furukawa K. Physiotherapy management focusing on proprioceptive impairment in a patient with gait and balance impairments following stroke: A case report. Physiother Theory Pract 2024:1-15. [PMID: 38516762 DOI: 10.1080/09593985.2024.2332792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 03/11/2024] [Indexed: 03/23/2024]
Abstract
BACKGROUND Proprioceptive impairment contributes to gait and balance impairments in patients with stroke. Diagnosis functional impairments and evaluation treatment efficacy require quantitative proprioception assessment. However, proprioception assessment has remained limited to ordinal scale measurement, with a lack of ratio scale measurements. PURPOSE This case report describes a physiotherapy management program focusing on proprioceptive impairment in patients with stroke using quantitative tests such as Threshold to Detect Passive Motion (TDPM) and Joint Position Sense (JPS). CASE DESCRIPTION A63-year-old male patient with an acute pontine lacunar infarction was admitted to our hospital. His muscle strength, selective movement, and trunk activity were preserved. However, the Berg Balance Scale (BBS) and Gait Assessment andIntervention Tool (GAIT) score were 42 and 9 points, observing balance impairment and the buckling knee pattern with hip ataxia during gait. Based on these, TDPM and JPS using image capture were performed. In physiotherapeuticdiagnosis, proprioceptive impairments in the hip and knee joints were the primary functional impairments related to balance and gait. To address these proprioceptive impairments, a 13-day treatment protocol incorporating transcutaneous electrical nerve stimulation (intensity: sensory threshold, frequency: 100 Hz) targeting the quadriceps femoris was performed. OUTCOMES The patient was discharged after achieving independent ambulation and improvement in BBS (56 points) and GAIT (2 points) scores, exceeding the minimum clinically important difference. Recovery of proprioceptive impairment corresponded withimproved balance and gait ability. CONCLUSION Quantitatively evaluating proprioceptive impairments may provide novel rehabilitation for patients with stroke who have proprioceptive impairments and contribute to clinical decision-making.
Collapse
Affiliation(s)
- Aisuke Takahashi
- Department of Medical Rehabilitation, Ohara General Hospital, Fukushima, Japan
| | - Shun Kitsunai
- Department of Medical Rehabilitation, Ohara General Hospital, Fukushima, Japan
| | - Hikaru Kawana
- Department of Medical Rehabilitation, Ohara General Hospital, Fukushima, Japan
| | - Naoshi Saito
- Department of Neurology, Ohara General Hospital, Fukushima, Japan
| | - Akioh Yoshihara
- Department of Neurology, Ohara General Hospital, Fukushima, Japan
| | - Katsuhiro Furukawa
- Department of Physical Therapy, Faculty of Health Sciences, Iryo Sosei University, Fukushima, Japan
| |
Collapse
|
2
|
Shiba H, Furukawa K, Tamaki S, Takahashi M. Triple-furrowed tongue in myasthenia gravis. QJM 2023; 116:534-535. [PMID: 36919764 DOI: 10.1093/qjmed/hcad035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 03/06/2023] [Indexed: 03/16/2023] Open
Affiliation(s)
- H Shiba
- Department of Neurology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan and Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa,Chino-shi, Nagano-ken, 391-8503, Japan
| | - K Furukawa
- Department of Neurology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| | - S Tamaki
- Department of Neurology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| | - M Takahashi
- Department of Neurology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| |
Collapse
|
3
|
Furukawa K. Human resource challenges for physical therapists in Japan: a hybrid time-series and system dynamics analyses for the near, mid and long-term horizons. Physiother Theory Pract 2023; 39:504-517. [PMID: 35040715 DOI: 10.1080/09593985.2021.2023924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION There have been growing concerns that the present annual supply of more than 14,000 physical therapists in Japan may signal a potential human resource challenge. The assumption that any increase in supply would be sustained by an increase in demand from an aging population has never been adequately investigated. PURPOSE The aim of this study was to investigate the human resource challenges faced by physical therapists in Japan, and to develop forecasting models (low, mid and high-growth) for the near (5-year), mid (20-year) and long-term (40-year) event horizons. METHODS All human resource data were extracted from publicly available sources from January to May 2020 and categorized according to actual and forecasted supply and strength of demand variables using s system dynamics approach. The actual supply variables were used to validate the forecasted supply using time-series analysis. RESULTS The increase in forecasted supply is expected to be most severe for the high growth scenario, particularly after the mid-term horizon. The forecasted strength of demand may be expected to decrease in both the total and aged populations. CONCLUSION The increase in supply of PTs in Japan over the past 55-year period, and the forecasted increase over the next 45 years is still a cause for concern. The assumption that any increase in supply would be sustained by an aging population was not supported by the results of this study. These results also suggest that the possibility of a human resource challenge may arise after the mid-term event horizon.
Collapse
Affiliation(s)
- Katsuhiro Furukawa
- Department of Physical Therapy, Faculty of Health Sciences, Iryo Sosei University, Iwaki-shi, Fukushima, Japan
| |
Collapse
|
4
|
Yokoyama N, Sato D, Katada T, Otani T, Furukawa K, Hashidate H. Gastrointestinal: Melanotic schwannoma of the pancreas associated with Carney complex: A cause of acute neoplastic symptom. J Gastroenterol Hepatol 2023; 38:7. [PMID: 35615762 DOI: 10.1111/jgh.15888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 05/07/2022] [Indexed: 01/19/2023]
Affiliation(s)
- N Yokoyama
- Department of Digestive Surgery, Niigata City General Hospital, Niigata, Japan
| | - D Sato
- Department of Digestive Surgery, Niigata City General Hospital, Niigata, Japan
| | - T Katada
- Department of Digestive Surgery, Niigata City General Hospital, Niigata, Japan
| | - T Otani
- Department of Digestive Surgery, Niigata City General Hospital, Niigata, Japan
| | - K Furukawa
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata, Japan
| | - H Hashidate
- Department of Pathology, Niigata City General Hospital, Niigata, Japan
| |
Collapse
|
5
|
Takada I, Miyazaki T, Kanzawa H, Shigefuku S, Namikawa-Kanai H, Matsubara T, Ono S, Nakajima E, Morishita Y, Honda A, Furukawa K, Ikeda N. EP16.04-009 The Proliferative Effect of 27-Hydroxycholesterol as a Selective Estrogen Receptor Modulator on Pathology of NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Nakajima E, Sugita M, Morishita Y, Miyazaki T, Kanzawa H, Kawaguchi Y, Ono S, Hirsch F, Ikeda N, Furukawa K. EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Hoang T, Ichinose K, Morimoto S, Furukawa K, Le L, Kawakami A. POS0746 MEASUREMENT OF ANTI-SUPRABASIN ANTIBODIES, MULTIPLE CYTOKINES AND CHEMOKINES AS POTENTIAL PREDICTIVE BIOMARKERS FOR NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is multifactorial and involves diverse cytokines, autoantibodies and immune complexes inducing blood-brain barrier (BBB) dysfunction, neuroendocrine-immune imbalance, vascular occlusion, tissue, and neuronal damage. Several pro-inflammatory cytokines have been implicated in the pathogenesis of NPSLE [1]. Previously we have shown that the titer of anti-suprabasin (SBSN) antibodies in cerebrospinal fluid (CSF) of NPSLE patients was significantly higher than in SLE, MS and NPH groups [2]. However, distinguishing NPSLE from other neuropsychiatric conditions with different etiologies is challenging.ObjectivesThis study determined the most critical serum biomarkers for the development of NPSLE as they may have clinical utility prior to the onset of neuropsychiatric symptoms.MethodsWe retrospectively analyzed 35 NPSLE patients, 34 SLE patients, 20 viral meningitis (VM) patients, and 16 relapsing-remitting multiple sclerosis (MS) patients. We measured anti-SBSN antibodies concentrations in serum by using Luciferase immunoprecipitation system (LIPS) assay. The serum concentrations of cytokines/chemokines were measured by using multiplex bead-based assay. All the clinical information and laboratory tests were collected at the time of admission.ResultsThe Bayesian posterior mean and 95% HPDI of the cut-off of AI and its PPV and 1-NPV values were 5.26 (3.68;7.17), 0.87, (0.72; 1.0) and 0.44, (0.36; 0.5), respectively (Figure 1).Figure 1.Summary of the posterior distribution of the cutoff of AI and its predictive value (1-NPV and PPV). The 95% HPDI is shown as the thick black horizontal line with the boundaries written above the lineAmong analyzed biomarkers, VEGF had the highest sparsity-oriented important learning (SOIL) importance, followed by AI, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNFα, MIP-1α (Figure 2).Figure 2.Top 10 biomarkers having highest SOIL importance in prediction of NPSLE.Abbreviations• AI: anti-SBSN antibody index• PPV: positive predictive• NPV: negative predictive value• SOIL: sparsity-oriented important learning• IL: interleukin•MIP: macrophage inflammatory protein• sCD40L: soluble CD40 ligand• MDC: macrophage-derived chemokine• VEGF: vascular endothelial growth factor• MDC: macrophage-derived chemokine• TNF: Tumor necrosis factorConclusionOur data demonstrated the ranking of serum biomarkers for the prediction of NPSLE. The most essential biomarkers are VEGF, anti-SBSN antibodies, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNFα, MIP-1α.References[1]Govoni M, Hanly JG: Rheumatology (Oxford), 2020: 59(Suppl5):v52-v62.[2]Ichinose K, et al: Clinical immunology, 2018; 193:123-130.Disclosure of InterestsNone declared
Collapse
|
8
|
Nunohiro T, Furukawa K, Uchida M, Kuwasaki S, Kusumoto S, Furudono S, Suenaga H, Takeno M, Takeshita S. Liver stiffness assessed by Fibrosis-4 index predicts heart failure in AMI patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehab849.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
It has been recently reported that the liver stiffness, which reflects increased central venous pressure, measured by transient elastography increases along with decompensated heart failure (HF) developing and decreases with clinical improvement. A simple index for the assessment of liver stiffness and/or impairment of liver reserve may be useful in patients with HF. We calculated each patient´s FIB4 index(F4I) using the following formula: (age (years)× aspartate aminotransferase (IU/L)/platelet count (109/L)× square root of alanine aminotransferase (IU/L)). Patients with an F4I≥2.67 were classified into the high F4I group and these patients were strongly suspected to have non-alcoholic fatty liver disease (NAFLD). NAFLD is also said to be a form of metabolic syndrome expressed in the liver. And lately NAFLD is associated with increased risk of acute myocardial infarction (AMI) and stroke and cardiovascular surrogate markers. But Little is known about F4I with the influence of AMI prognosis. This study included 167 AMI patients who underwent primary percutaneous coronary intervention within 24h of onset. Consecutive patients were divided into two groups based on their F4I at discharge: First group (2.67 ≤F4I, n = 27), second group (F4I <2.67, n = 140) . And we assessed the association between F4I and CV events including cardiac death, recurrent AMI, recurrent PCI (TLR) and re-hospitalization of heart failure during 13 months. Result: High F4I (2.67≤ F4I ,19% VS F4I <2.67, 6%: P = 0.045) related to the re-hospitalization of heart failure. Univariate odds ratio was 3.45. F4I is significantly related to the re-hospitalization of heart failure. Conclusion: A simple index F4I is significantly related to the prognosis of adverse cardiac events after AMI patients. Abstract Figure. Predictor of Re-hospitalization of HF
Collapse
Affiliation(s)
- T Nunohiro
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - K Furukawa
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - M Uchida
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - S Kuwasaki
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - S Kusumoto
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - S Furudono
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - H Suenaga
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - M Takeno
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| | - S Takeshita
- Nagasaki Harbor Medical Center, Nagasaki, Japan
| |
Collapse
|
9
|
Furukawa K, Yamamura T, Nakamura M, Kawashima H, Fujishiro M. Gastrointestinal: Idiopathic omental hemorrhage. J Gastroenterol Hepatol 2022; 37:282. [PMID: 34390039 DOI: 10.1111/jgh.15639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 07/22/2021] [Indexed: 12/09/2022]
Affiliation(s)
- K Furukawa
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Yamamura
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Nakamura
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Kawashima
- Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan
| | - M Fujishiro
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
10
|
Takeda Y, Furukawa K. Clinical reliability and usability of smartphone goniometers for hip range of motion measurement. J Phys Ther Sci 2022; 34:433-439. [PMID: 35698549 PMCID: PMC9170486 DOI: 10.1589/jpts.34.433] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 03/06/2022] [Indexed: 11/24/2022] Open
Affiliation(s)
- Yugo Takeda
- Iwaki Yumoto Hospital: 6 Daiyama, Joban-Yumoto-cho, Iwaki City, Fukushima 972-8321, Japan
| | | |
Collapse
|
11
|
Yamagami K, Nomura A, Kometani M, Shimojima M, Sakata K, Usui S, Furukawa K, Takamura M, Okajima M, Watanabe K, Yoneda T. Early detection of exacerbation of the severe acute respiratory syndrome coronavirus 2 infection using Fitbit (DEXTERITY pilot study). Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Some patients with coronavirus disease 2019 (COVID-19) experienced sudden death because of sudden symptom deterioration. Thus, an alarm system that could detect early signs of COVID-19 exacerbation beforehand, to prevent serious illness or death of patients while receiving outpatient treatment at home or in hotels is necessary. Here, we tested whether estimated oxygen variations (EOV), a relative physiological scale that represents users' blood oxygen saturation level during sleep measured by Fitbit, predicted COVID-19 symptom exacerbation. Study period was from August to November 2020. We enrolled 23 COVID-19 patients diagnosed by SARS-CoV-2 polymerase chain reaction-positive (mean age ± standard deviation, 50.9±20 years; 70% female), let each patient wore the Fitbit for 30 days; COVID-19 symptoms were exacerbated in 6 (26%). High EOV signal (a patient's oxygen level exhibits significant dip and recovery within the index period) had 80% sensitivity before symptom exacerbations, whereas resting heart rate signal only had 50% sensitivity. Coincidental obstructive sleep apnea syndrome confirmed by polysomnography was detected in a patient by consistently high EOV signals. This pilot study successfully detected early COVID-19 symptoms exacerbation by measuring EOV and may help to identify early signs of COVID-19 exacerbation.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): The investigational device used in this study, Fitbit Charge 3, was provided by Fitbit Japan. Summary of high EOV signals and eventsThe clinical course of COVID-19
Collapse
Affiliation(s)
- K Yamagami
- Kanazawa University Hospital, Kanazawa, Japan
| | - A Nomura
- Kanazawa University Hospital, Kanazawa, Japan
| | - M Kometani
- Kanazawa University Graduate School of Medicine, Department of Health Promotion and Medicine of the Future, Kanazawa, Japan
| | - M Shimojima
- Kanazawa University Hospital, Kanazawa, Japan
| | - K Sakata
- Kanazawa University Hospital, Kanazawa, Japan
| | - S Usui
- Kanazawa University Hospital, Kanazawa, Japan
| | - K Furukawa
- Health Care Center, Japan Advanced Institute of Science and Technology, Kanazawa, Japan
| | - M Takamura
- Kanazawa University Hospital, Kanazawa, Japan
| | - M Okajima
- Kanazawa University Hospital, Intensive Care Unit, Kanazawa, Japan
| | - K Watanabe
- JCHO Kanazawa Hospital, Kaznazawa, Japan
| | - T Yoneda
- Kanazawa University Graduate School of Medicine, Department of Health Promotion and Medicine of the Future, Kanazawa, Japan
| |
Collapse
|
12
|
Katsurada N, Tachihara M, Jimbo N, Yamamoto M, Yoshioka J, Mimura C, Takata N, Sato H, Furukawa K, Otoshi T, Yumura M, Kiriu T, Yasuda Y, Tanaka T, Nagano T, Nishimura Y, Kobayashi K. P02.05 Yield of Tumor Samples With A Guide-sheath in Endobronchial Ultrasound Transbronchial Biopsy For Non-small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Mimura C, Katsurada M, Tachihara M, Katsurada N, Takata N, Sato H, Yoshioka J, Furukawa K, Yumura M, Otoshi T, Yasuda Y, Kiriu T, Hazama D, Nagano T, Yamamoto M, Nishimura Y, Kobayashi K. FP15.01 Randomized Single-Blind Comparative Study of Midazolam Plus Pethidine Combination and Midazolam During Bronchoscopy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Shimizu T, Koga T, Furukawa K, Horai Y, Fujikawa K, Okada A, Okamoto M, Endo Y, Tsuji S, Takatani A, Umeda M, Fukui S, Sumiyoshi R, Kawashiri SY, Iwamoto N, Igawa T, Ichinose K, Tamai M, Sakamoto N, Nakamura H, Origuchi T, Mukae H, Kuwana M, Kawakami A. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. J Intern Med 2021; 289:206-220. [PMID: 32691471 DOI: 10.1111/joim.13154] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 06/28/2020] [Accepted: 06/29/2020] [Indexed: 12/21/2022]
Abstract
BACKGROUND Polymyositis/dermatomyositis (PM/DM) is an autoimmune disease that is sometimes complicated with rapidly progressive interstitial lung disease (RPILD). However, serum and lung biomarkers that can predict RPILD development remain unclear. OBJECTIVES To determine potential serum and lung biomarkers that can predict RPILD development in patients with PM/DM-ILD. METHODS In total, 49 patients with PM/DM-ILD were enrolled. We measured the serum levels of 41 cytokines/chemokines, ferritin and anti-MDA5 antibody, compared them between the RPILD (n = 23) and non-RPILD (n = 26) groups, and ranked them by their importance through random forest analysis. To distinguish the two groups, we determined biomarker combinations by logistic regression analysis. We also measured the bronchoalveolar lavage fluid (BALF) levels of 41 cytokines/chemokines. Using immunohistochemistry, we examined IL-15 expression in lung tissues. The IL-15 production was also investigated using A549 and BEAS-2B cells. RESULTS The RPILD group had significantly higher IL-15, IL-1RA, IL-6, CXCL10, VCAM-1, anti-MDA5 antibody and ferritin serum levels than the non-RPILD group, but it had a significantly low CCL22 level. Meanwhile, anti-MDA5 antibody, IL-15, CXCL8, CCL22, IL-1RA and ferritin were the best combination to distinguish the two groups. IL-15 and CCL22 were also predictive marker for RPILD development in anti-MDA5 antibody-positive patients. Additionally, the RPILD group had significantly high IL-15 levels in BALF. The lung tissues expressed IL-15, which increased after cytokine stimulation in the A549 cells. CONCLUSION This study identified a combination of biomarkers predicting PM/DM-RPILD progression, and IL-15 is an important cytokine for predicting RPILD development and reflecting ILD severity.
Collapse
Affiliation(s)
- T Shimizu
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.,Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
| | - T Koga
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.,Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - K Furukawa
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Y Horai
- Department of Rheumatology, National Hospital Organization Nagasaki Medical Center, Omura, Japan
| | - K Fujikawa
- Department of Rheumatology, Japan Community Health care Organization Isahaya General Hospital, Isahaya, Japan
| | - A Okada
- Department of Rheumatology, Japan Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
| | - M Okamoto
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Y Endo
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - S Tsuji
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - A Takatani
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - M Umeda
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - S Fukui
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - R Sumiyoshi
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.,Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
| | - S-Y Kawashiri
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - N Iwamoto
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - T Igawa
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.,Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
| | - K Ichinose
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - M Tamai
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - N Sakamoto
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - H Nakamura
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - T Origuchi
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.,Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - H Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - M Kuwana
- Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
| | - A Kawakami
- From the, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| |
Collapse
|
15
|
Koga T, Endo Y, Furukawa K, Agematsu K, Yachie A, Masumoto J, Migita K, Kawakami A. SAT0527 COMBINED EFFECT OF COMMON VARIANTS IN EXON 2 OR EXON 3 AND A PATHOGENIC MUTATION IN EXON 10 OF THE MEDITERRANEAN FEVER GENE ON INFLAMMASOME ACTIVATION IN JAPANESE PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Familial Mediterranean fever (FMF) is an autoinflammatory disease that is caused by Mediterranean fever (MEFV) gene mutations. It is characterized by recurrent and self-limiting febrile attacks within a short period. Although the pathologic significance ofMEFVexon 2 or exon 3 common variants in patients with FMF is modest and these variants are usually associated with less severe clinical presentations of FMF (1, 2), their combined effects with pathogenic mutation in exon 10 remain to be evaluated.Objectives:To determine the combined effect of common variants on clinical manifestations and inflammasome activity, we compared the clinical and laboratory characteristics between the coexistence and non-coexistence ofMEFVexon 2 or exon 3 variants in patients with FMF that had a heterozygousMEFVexon 10 mutation.Methods:We excluded patients with FMF that had twoMEFVexon 10 mutations in one or more alleles and those withMEFVvariants in exons other than in exons 2, 3, or 10. Finally, we reviewed 131 Japanese patients with FMF that had a heterozygousMEFVexon 10 mutation, and they were divided into the groups with and withoutMEFVexon 2 or exon 3 variants of 34 and 97, respectively. All enrolled patients had only a heterozygous M694I mutation in exon 10 of theMEFVgene. We measured serum IL-18 levels at remission without febrile attacks in the groups with and withoutMEFVexon 2 or exon 3 variants of 9 and 31, respectively.Results:In the univariate analysis, the group with variants in exon 2 or exon 3 had significantly earlier onset (16.0 years v.s. 20.5 years, p = 0.04), a higher percentage of thoracic pain with febrile attacks (68% v.s. 44%, p = 0.02), a higher frequency of attack (1.0/month v.s. 0.5/month, p = 0.02), and a higher IL-18 level in the serum at remission (606.3 pg/ml v.s. 168.4 pg/ml, p = 0.04, Figure 1) compared to the group without these variants. Importantly, multivariate analyses showed that the coexistence ofMEFVexon 2 or exon 3 variants and an exon 10 mutation was independently and significantly associated with earlier onset of FMF (p = 0.049) and thoracic pain (p = 0.03).Figure 1.Conclusion:Our results suggest that the coexistence ofMEFVexon 2 or exon 3 variants and aMEFVexon 10 mutation has combined effects on inflammasome activation in the Japanese population.References:[1]Migita K, Uehara R, Nakamura Y, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore). 2012 Nov;91(6):337-43.[2]Shinar Y, Livneh A, Langevitz P, Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol. 2000;27(7):1703.Disclosure of Interests:None declared
Collapse
|
16
|
Tanaka Y, Matsubara R, Furukawa K, Satonaka S, Kasaoka S. The influence of viscosity-enhancing agents on oral absorption of drugs. Pharmazie 2019; 74:661-664. [PMID: 31739832 DOI: 10.1691/ph.2019.9097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The objective of this study was to evaluate the influence of viscosity-enhancing agents on oral absorption of metoprolol (MPL) and bisoprolol (BPL). Although the viscosity values were similar for MPL and BPL in hydroxypropyl methylcellulose (HPMC, 1.2 % (w/w)) and polyvinyl alcohol (PVA, 8.8 % (w/w)) solutions, the order of diffusion rate constants of the drugs in media were phosphate buffer solution (reference) > HPMC solution > PVA solution. In in vivo rat intestinal absorption experiments showed that the Cmax and AUC values of the drugs were lowest when they were administered into the rat jejunum in a PVA solution. In vitro binding studies showed that this may have been due to adsorption of the drugs to PVA molecules, resulting in decreased free fractions of the drugs. Our results indicated that intestinal absorption of the drugs in PVA solution was influenced both by decreased diffusion of the drugs and by interaction with PVA. Since various viscosity-enhancing agents are widely used as pharmaceutical and food additives, these findings may be of significance for understanding therapeutic efficacy and safety of oral drug products.
Collapse
|
17
|
Terashima M, Nakamura K, Hatakeyama K, Furukawa K, Fujiya K, kamiya S, Hikage M, Tanizawa Y, Bando E, Oshima K, Urakami K, Machida N, Yasui H, Yamaguchi K. Prediction of S-1 adjuvant chemotherapy efficacy in stage II/III gastric cancer treatment based on comprehensive gene expression analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
18
|
Shimao R, Muroi H, Furukawa K, Toyomizu M, Kikusato M. Effects of low-dose oleuropein diet supplementation on the oxidative status of skeletal muscles and plasma hormonal concentration of growing broiler chickens. Br Poult Sci 2019; 60:784-789. [PMID: 31524499 DOI: 10.1080/00071668.2019.1662886] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. Oleuropein (Ole) is a major phenolic compound in Olea europaea, with anti-oxidative, anti-obesity, and anti-inflammatory properties. To explore the effect of Ole on the physiology and metabolism of poultry, this study, evaluated the effects of feeding low-dose Ole on the growth performance, metabolic hormonal status, muscle oxidative status in growing broiler chickens.2. Thirty-two 8-day-old chickens were assigned to four different treatments, and fed either 0 (control), 0.1, 0.5, or 2.5 ppm Ole-supplemented diets for 2 weeks.3. There were no differences in the body weight gain, feed consumption, and feed efficiency during the feeding periods between the groups tested. Birds fed Ole 0.5- and 2.5 ppm-supplemented diets exhibited a significant decrease in muscle carbonyl content compared to the control group. In the group fed Ole 0.5 ppm, the mRNA expression levels of mitochondrial ROS-reducing factors: avian uncoupling protein and manganese superoxide dismutase, as well as peroxisome proliferator-activated receptor γ coactivator 1-α, sirtuin-1 and -3 (each of which co-ordinately induce the transcription of the previous two factors) were upregulated compared to the control group, and the changes were independent of plasma noradrenaline and thyroid hormone levels. The group fed Ole-2.5 ppm did not show such transcriptional changes, but exhibited a higher corticosterone concentration.4. This study demonstrates that ingesting a low dose of Ole can reduce muscle oxidative damage, and that the suppression machinery may differ depending on the amount of Ole ingested by growing broiler chickens.
Collapse
Affiliation(s)
- R Shimao
- Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan
| | - H Muroi
- Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan
| | - K Furukawa
- Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan
| | - M Toyomizu
- Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan
| | - M Kikusato
- Animal Nutrition, Life Sciences, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan
| |
Collapse
|
19
|
Ezura M, Kikuchi A, Ishiki A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Kobayashi M, Tano O, Nakashima I, Mugikura S, Iwata R, Taki Y, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome. Eur J Neurol 2019; 26:1205-1211. [PMID: 30980575 DOI: 10.1111/ene.13966] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 04/04/2019] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND PURPOSE Corticobasal syndrome (CBS) is pathologically characterized by tau deposits in neuronal and glial cells and by reactive astrogliosis. In several neurodegenerative disorders, 18 F-THK5351 has been observed to bind to reactive astrocytes expressing monoamine oxidase B. In this study, the aim was to investigate the progression of disease-related pathology in the brains of patients with CBS using positron emission tomography with 18 F-THK5351. METHODS Baseline and 1-year follow-up imaging were acquired using magnetic resonance imaging and positron emission tomography with 18 F-THK5351 in 10 subjects: five patients with CBS and five age-matched normal controls (NCs). RESULTS The 1-year follow-up scan images revealed that 18 F-THK5351 retention had significantly increased in the superior parietal gyrus of the patients with CBS compared with the NCs. The median increases in 18 F-THK5351 accumulation in the patients with CBS were 6.53% in the superior parietal gyrus, 4.34% in the precentral gyrus and 4.33% in the postcentral gyrus. In contrast, there was no significant increase in the regional 18 F-THK5351 retention in the NCs. CONCLUSIONS Longitudinal increases in 18 F-THK5351 binding can be detected over a short interval in the cortical sites of patients with CBS. A monoamine oxidase B binding radiotracer could be useful in monitoring the progression of astrogliosis in CBS.
Collapse
Affiliation(s)
- M Ezura
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - A Kikuchi
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - A Ishiki
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - N Okamura
- Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.,Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - T Hasegawa
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - R Harada
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Watanuki
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - Y Funaki
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - K Hiraoka
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - T Baba
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - N Sugeno
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - R Oshima
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Yoshida
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - J Kobayashi
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - M Kobayashi
- Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - O Tano
- Department of Neurology, Sendai Medical Center, Sendai, Japan
| | - I Nakashima
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.,Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - S Mugikura
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - R Iwata
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - Y Taki
- Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - K Furukawa
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.,Division of Community of Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - H Arai
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - S Furumoto
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - M Tashiro
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
| | - K Yanai
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Kudo
- Division of Neuroimaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - A Takeda
- Department of Neurology, National Hospital Organization, Sendai Nishitaga Hospital, Sendai, Japan
| | - M Aoki
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
| |
Collapse
|
20
|
Kodama S, Fujihara K, Horikawa C, Harada M, Ishiguro H, Kaneko M, Furukawa K, Matsubayashi Y, Matsunaga S, Shimano H, Tanaka S, Kato K, Sone H. Network meta-analysis of the relative efficacy of bariatric surgeries for diabetes remission. Obes Rev 2018; 19:1621-1629. [PMID: 30270528 DOI: 10.1111/obr.12751] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Revised: 07/05/2018] [Accepted: 07/11/2018] [Indexed: 01/06/2023]
Abstract
BACKGROUND Bariatric surgery leads to a higher remission rate for type 2 diabetes mellitus than non-surgical treatment. However, it remains unsolved which surgical procedure is the most efficacious. This network meta-analysis aimed to rank surgical procedures in terms of diabetes remission. METHODS AND FINDINGS We electronically searched for randomized controlled trials in which at least one surgical treatment was included among multiple arms and the diabetes remission rate was included in study outcomes. A random-effects network meta-analysis was performed within a frequentist framework. The hierarchy of treatments was expressed as the surface under the cumulative ranking curve value. Results of the analysis of 25 eligible randomized controlled trials that covered non-surgical treatments and eight surgical procedures (biliopancreatic diversion [BPD], BPD with duodenal switch, Roux-en Y gastric bypass, mini gastric bypass [mini-GBP], laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, greater curvature plication and duodenal-jejunal bypass) showed that BPD and mini-GBP had the highest surface under the cumulative ranking curve values among the eight surgical treatments. CONCLUSION Current network meta-analysis indicated that BPD or mini-GBP achieved higher diabetes remission rates than the other procedures. However, the result needs to be interpreted with caution considering that these procedures were in the minority of bariatric surgeries.
Collapse
Affiliation(s)
- S Kodama
- Department of Laboratory Medicine and Clinical Epidemiology for Prevention of Noncommunicable Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - K Fujihara
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - C Horikawa
- Department of Health and Nutrition, Faculty of Human Life Studies, University of Niigata Prefecture, Niigata, Japan
| | - M Harada
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - H Ishiguro
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - M Kaneko
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - K Furukawa
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - Y Matsubayashi
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - S Matsunaga
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| | - H Shimano
- Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan
| | - S Tanaka
- Department of Clinical Trial, Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan
| | - K Kato
- Department of Laboratory Medicine and Clinical Epidemiology for Prevention of Noncommunicable Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - H Sone
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan
| |
Collapse
|
21
|
Suzuki K, Yuki S, Nakano S, Kawamoto Y, Nakatsumi H, Hatanaka K, Ando T, Furukawa K, Ishiguro A, Ohta T, Eto K, Nakajima J, Nakamura M, Sogabe S, Kato K, Tateyama M, Kato S, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Kato Y, Furukawa K, Amemiya R, Furumoto H, Shigefuku S, Ikeda N. P3.16-27 Clinical Outcome of Preoperative Intervention Bronchoscopy Followed by Surgery. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Usami E, Kimura M, Furukawa K, Teramachi H, Yoshimura T. Controllable vitamin K deficiency under high-dose oral menatetrenone administration - a case report. Pharmazie 2018; 73:234-240. [PMID: 29609692 DOI: 10.1691/ph.2018.7994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Vitamin (V) K deficiency may cause severe bleeding tendencies, which necessitates extreme caution. We report a case of a 30-year-old man diagnosed with VK deficiency of unknown etiology. He was treated with intravenous menatetrenone three times a week in an outpatient setting for about 1 year and 9 months. Eventually, he developed an allergic reaction to intravenous menatetrenone and was under steroid therapy. In order to reduce his hospital visits and discontinue steroid use, the pharmacist proposed to change the method of menatetrenone administration from intravenous to oral (high dose). The change in treatment method has greatly improved the patient's quality of life.
Collapse
|
25
|
Yoshita H, Yuki S, Yagisawa M, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Dazai M, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Sakata Y, Komatsu Y. First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Nakajima E, Sugita M, Furukawa K, Takahashi H, Kawaguchi Y, Ohira T, Ikeda N, Hirsch F, Franklin W. P2.03-019 Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Mitsuhashi M, Sawamoto N, Shima A, Furukawa K, Kambe D, Takahashi R. Severity of motor symptoms and degree of dopaminergic damage in the terminal and the soma in advanced Parkinson's disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Furukawa K, Sawamoto N, Shima A, Kambe D, Takahashi R. Cognitive impairments in patients with increased tendency to fall in Parkinson's disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Yuki S, Komatsu Y, Yagisawa M, Tsuji Y, Harada K, Hatanaka K, Okuda H, Hosokawa A, Ogawa K, Furukawa K, Minami S, Ishiguro A, Honda T, Ohta T, Dazai M, Eto K, Sasaki T, Nakajima J, Sakamoto N, Sakata Y. A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
|
31
|
Kato H, Kato Y, Yoneyama R, Ishikawa R, Kojika M, Miyajima K, Takizawa N, Furukawa K. Review of PDT for lung cancer and future. Photodiagnosis Photodyn Ther 2017. [DOI: 10.1016/j.pdpdt.2017.01.067] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Ando T, Yuki S, Nakatsumi H, Muranaka T, Hosokawa A, Tsuji Y, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakata Y, Komatsu Y. 172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, Yanai K, Kudo Y, Arai H, Furumoto S, Tashiro M, Furukawa K. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur J Neurol 2016; 24:130-136. [DOI: 10.1111/ene.13164] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Accepted: 08/29/2016] [Indexed: 12/26/2022]
Affiliation(s)
- A. Ishiki
- Department of Geriatrics and Gerontology; Institute of Development, Aging and Cancer; Tohoku University; Sendai Japan
| | - R. Harada
- Division of Neuro-imaging; Institute of Development, Aging and Cancer; Tohoku University; Sendai Japan
| | - N. Okamura
- Department of Pharmacology; Tohoku University School of Medicine; Sendai Japan
- Division of Pharmacology; Faculty of Medicine; Tohoku Medical and Pharmaceutical University; Sendai Japan
| | - N. Tomita
- Department of Geriatrics and Gerontology; Institute of Development, Aging and Cancer; Tohoku University; Sendai Japan
| | - C. C. Rowe
- Centre for PET; Austin Health; Heidelberg Victoria Australia
| | - V. L. Villemagne
- Centre for PET; Austin Health; Heidelberg Victoria Australia
- The Florey Institute of Neuroscience and Mental Health; The University of Melbourne; Melbourne Victoria Australia
| | - K. Yanai
- Department of Pharmacology; Tohoku University School of Medicine; Sendai Japan
| | - Y. Kudo
- Division of Neuro-imaging; Institute of Development, Aging and Cancer; Tohoku University; Sendai Japan
| | - H. Arai
- Department of Geriatrics and Gerontology; Institute of Development, Aging and Cancer; Tohoku University; Sendai Japan
| | - S. Furumoto
- Division of Radiopharmaceutical Chemistry; Cyclotron and Radioisotope Center; Tohoku University; Sendai Japan
| | - M. Tashiro
- Division of Cyclotron Nuclear Medicine; Cyclotron and Radioisotope Center; Tohoku University; Sendai Japan
| | - K. Furukawa
- Department of Geriatrics and Gerontology; Institute of Development, Aging and Cancer; Tohoku University; Sendai Japan
- Division of Community of Medicine; Faculty of Medicine; Tohoku Medical and Pharmaceutical University; Sendai Japan
| |
Collapse
|
34
|
Kato Y, Nishimura T, Ohira T, Nakamura H, Tojo H, Kawamura T, Kodama T, Marko-Varga G, Furukawa K, Ikeda N. 476. Highly enhanced ErbB signaling pathway was unveiled in lepidic predominant invasive lung adenocarcinoma. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
35
|
Suzuki D, Furukawa K, Furukawa A, Shimizu H, Otsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Sakai N, Kagawa S, Nojima H, Miyazaki M. SUN-P144: Does the Modified Glasgow Prognostic Score have a Prognostic Role in Gallbladder Cancer? Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30487-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Furukawa A, Furukawa K, Suzuki D, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Sakai N, Kagawa S, Nojima H, Miyazaki M. MON-P233: Impact of Immunonutrition on Infectious Complications in Sarcopenic Patients Undergoing Pancreaticoduodenectomy. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30867-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Furukawa K, Furukawa A, Suzuki D, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Sakai N, Kagawa S, Nojima H, Miyazaki M. MON-P236: Influence Of Sarcopenia On Infectious Complications in Patients Undergoing Pancreaticoduodenectomy. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30870-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Kitamura K, Okuno Y, Yoshida K, Sanada M, Shiraishi Y, Muramatsu H, Kobayashi R, Furukawa K, Miyano S, Kojima S, Ogawa S, Kunishima S. Functional characterization of a novel GFI1B mutation causing congenital macrothrombocytopenia. J Thromb Haemost 2016; 14:1462-9. [PMID: 27122003 DOI: 10.1111/jth.13350] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Accepted: 04/11/2016] [Indexed: 01/04/2023]
Abstract
UNLABELLED Essentials Two groups recently reported GFI1B as a novel causative gene for congenital macrothrombocytopenia. We performed functional analysis of a novel GFI1B mutation and previous mutations. An immunofluorescence analysis of the platelet CD34 expression can be useful as a screening test. Mutant-transduced megakaryocytes produced enlarged proplatelet tips which were reduced in number. SUMMARY Background GFI1B is an essential transcription factor for megakaryocyte and erythrocyte development. Two groups have recently identified GFI1B as a novel causative gene for congenital macrothrombocytopenia associated with α-granule deficiency. Methods We performed whole exome sequencing and identified a novel GFI1B p.G272fsX274 mutation in a family with macrothrombocytopenia, and a decreased number of platelet α-granules and abnormally shaped red blood cells. p.G272fsX274 and the previous two mutations all predicted disruption of an essential DNA-binding domain in GFI1B. We therefore performed functional studies to characterize the biochemical and biological effects of these three patient-derived mutations. Results An immunofluorescence analysis revealed decreased thrombospondin-1 and increased CD34 expression in platelets from our patient. Consistent with the previous studies, the three patient-derived mutants were unable to repress the expression of the reporter gene and had a dominant-negative effect over wild-type GFI1B. In addition, the three mutations abolished recognition of a consensus-binding site in gel shift assays. Furthermore, transduction of mouse fetal liver-derived megakaryocytes with the three GFI1B mutants resulted in the production of abnormally large proplatelet tips, which were reduced in number. Conclusions Our study provides further proof of concept that GFI1B is an essential protein for the normal development of the megakaryocyte lineage.
Collapse
Affiliation(s)
- K Kitamura
- Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
- Department of Biochemistry II, Graduate School of Medicine, Nagoya University, Nagoya, Japan
| | - Y Okuno
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Yoshida
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - M Sanada
- Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | - Y Shiraishi
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - H Muramatsu
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - R Kobayashi
- Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan
| | - K Furukawa
- Department of Biomedical Sciences, Chubu University College of Life and Health Sciences, Kasugai, Japan
| | - S Miyano
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Laboratory of Sequence Data Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Kojima
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - S Kunishima
- Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| |
Collapse
|
39
|
Abstract
In order to elucidate the cause and pathology of varicose veins in the lower limb, the terminal valves of the long saphenous vein in 36 patients with varicose veins and ten control cases have been examined by light and transmission electron microscopy. Valve failure in the varicose group was thought to start with a depression in the valvular commissure and to proceed to extension of this depression and expansion of the space between the two valves. It was further thought that, in this group, reversal and tortuosity of the valve cusps, hyperplasia of the collagen fibres and irregularity of the course of elastic fibre layers represented secondary changes. In almost all cases, intimal fibrous thickening was present in the vein wall, and this was histologically similar to so-called phlebosclerosis. It was further confirmed that the degree of intimal thickening was correlated to the disease period, with greater thickening noted at the region under greater pressure load. Phlebosclerosis seemed to be proportional to the size of stress and pressure load time.
Collapse
Affiliation(s)
| | | | | | - I. Yoshihama
- First Department of Pathology, Tokyo Medical College, Tokyo, Japan
| |
Collapse
|
40
|
Yuki S, Komatsu Y, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Tsuji Y, Hosokawa A, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakamoto N, Sakata Y. P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Noto Z, Tomihara K, Furukawa K, Noguchi M. Dyskeratosis congenita associated with leukoplakia of the tongue. Int J Oral Maxillofac Surg 2016; 45:760-3. [DOI: 10.1016/j.ijom.2015.12.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Revised: 10/05/2015] [Accepted: 12/08/2015] [Indexed: 10/22/2022]
|
42
|
Uwagawa T, Sakamoto T, Nakaseko Y, Takano Y, Furukawa K, Kanehira M, Onda S, Gocho T, Shiba H, Arakawa Y, Aiba K, Yanaga K. P-117 Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer. First report. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Furukawa K, Fujiwara T, Abe K, Kamijo M. The effect of vocalization on spinal excitation as measured by H wave. Physiother Theory Pract 2016; 32:218-22. [DOI: 10.3109/09593985.2016.1139022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
44
|
Hosokawa A, Yuki S, Kawamoto Y, Ando T, Muto O, Nakamura M, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Hayashi H, Fujikawa K, Kudo M, Honda T, Sakata Y, Komatsu Y. 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Horvath TA, Hirano T, Horvathova MD, Vomela J, Vyzula R, Cı́halová M, Dorociak F, Ebihara Y, Furukawa K, Habanec B, Ikeda N, Kakihana M, Klusáková J, Okada S, Rejthar A, Stratil D, Shaffi-Sahely A, Smajer B, Spelda S, Tsuboi M, Vagunda V, Wurst F, Kato H. Autofluorescence (safe) bronchoscopy and p21/ki-67 immunostaining related to carcinogenesis. Photodiagnosis Photodyn Ther 2015; 1:13-22. [PMID: 25048060 DOI: 10.1016/s1572-1000(04)00005-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Archival biopsy materials from 20 randomly selected asymptomatic volunteers from the Czech uranium miners (CZ UM) risk group (n=98) were examined for p21 and ki-67 immunostatning. There were 16 areas with normal respiratory epithelium and 22 areas with bronchial intra-epithelial neoplasia (IEN). Normal and IEN areas were identified by autofluorescence (System Autofluorescence Endoscopy, SAFE-1000) and monitored during 1998-2002. The majority of specimens from areas with normal autofluorescence intensity with ciliated columnar bronchial epithelium showed strong predominantly cytoplasmic p21 positivity. The SAFE monitoring divided areas of decreased autofluorescence intensity with early stage IEN lesions into two groups. Persistent lesions (P)-showing a spectrum of p21 cytoplasmic staining ranging from negative or isolated negativity to weak or moderate positivity combined with higher proliferative capacity proved by ki-67 nuclear staining. Disappearing lesions (D)-showing strong cytoplasmic p21 positivity and negative ki-67 staining. The IEN lesions were classified into three groups based on p21/ki-67 immunostaining: proliferative lesions at risk (R) with low or without p21 plasma immunostaining combined with high ki-67 nuclear reactivity; ambiguous lesions (A) including cases combining strong p21 cytoplasmic positivity with high ki-67 nuclear reactivity or p21 cytoplasmic negativity with ki-67 negativity staining patterns; the quiescent lesion group (Q) was characterized by strong p21 cytoplasmic positivity and negative ki-67 immunostaining.
Collapse
Affiliation(s)
- T A Horvath
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - T Hirano
- First Department of Surgery, Tokyo Medical University, Tokyo, Japan
| | - M D Horvathova
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - J Vomela
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - R Vyzula
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - M Cı́halová
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - F Dorociak
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - Y Ebihara
- Department of Histopathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| | - K Furukawa
- First Department of Surgery, Tokyo Medical University, Tokyo, Japan
| | - B Habanec
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - N Ikeda
- First Department of Surgery, Tokyo Medical University, Tokyo, Japan
| | - M Kakihana
- First Department of Surgery, Tokyo Medical University, Tokyo, Japan
| | - J Klusáková
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - S Okada
- Department of Histopathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
| | - A Rejthar
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - D Stratil
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - A Shaffi-Sahely
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - B Smajer
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - S Spelda
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - M Tsuboi
- First Department of Surgery, Tokyo Medical University, Tokyo, Japan
| | - V Vagunda
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - F Wurst
- Department of Surgery, University Hospital Bohunice, Masaryk Memorial Cancer Institute and University Oncology Center Brno, Žlutý kopec 7, CZ-65653 Brno, Czech Republic
| | - H Kato
- First Department of Surgery, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
46
|
Nakamura M, Yuki S, Nakatsumi H, Muto O, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31018-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
47
|
Hatanaka K, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto O, Meguro T, Iwanaga I, Tsuji Y, Sato A, Eto K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Okuda H, Kudo M, Sakata Y, Komatsu Y. P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Grant EJ, Ozasa K, Ban N, de González AB, Cologne J, Cullings HM, Doi K, Furukawa K, Imaoka T, Kodama K, Nakamura N, Niwa O, Preston DL, Rajaraman P, Sadakane A, Saigusa S, Sakata R, Sobue T, Sugiyama H, Ullrich R, Wakeford R, Yasumura S, Milder CM, Shore RE. A report from the 2013 international symposium: the evaluation of the effects of low-dose radiation exposure in the life span study of atomic bomb survivors and other similar studies. Health Phys 2015; 108:551-556. [PMID: 25811153 DOI: 10.1097/hp.0000000000000262] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The RERF International Low-Dose Symposium was held on 5-6 December 2013 at the RERF campus in Hiroshima, Japan, to discuss the issues facing the Life Span Study (LSS) and other low-dose studies. Topics included the current status of low-dose risk detection, strategies for low-dose epidemiological and statistical research, methods to improve communication between epidemiologists and biologists, and the current status of radiological studies and tools. Key points made by the participants included the necessity of pooling materials over multiple studies to gain greater insight where data from single studies are insufficient; generating models that reflect epidemiological, statistical, and biological principles simultaneously; understanding confounders and effect modifiers in the current data; and taking into consideration less studied factors such as the impact of dose rate. It is the hope of all participants that this symposium be used as a trigger for further studies, especially those using pooled data, in order to reach a greater understanding of the health effects of low-dose radiation.
Collapse
Affiliation(s)
- E J Grant
- *Radiation Effects Research Foundation, Hiroshima, Japan; †Tokyo Healthcare University, Tokyo, Japan; ‡U.S. National Cancer Institute, Bethesda, MD; §National Institute of Radiological Sciences, Chiba, Japan; **Fukushima Medical University, Fukushima, Japan; ††Hirosoft, Eureka, CA; ‡‡Osaka University, Osaka, Japan; §§University of Manchester, Manchester, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ogihara H, Karasuno H, Morishita K, Yokoi Y, Furukawa K, Fujiwara T, Ogoma Y. Combined effects of transcutaneous electrical nerve stimulation and stretching. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
50
|
Tarashima N, Sumitomo T, Ando H, Furukawa K, Ishida T, Minakawa N. Synthesis of DNA fragments containing 2′-deoxy-4′-selenonucleoside units using DNA polymerases: comparison of dNTPs with O, S and Se at the 4′-position in replication. Org Biomol Chem 2015; 13:6949-52. [DOI: 10.1039/c5ob00941c] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The first synthesis of 4′-selenoDNA was achieved using 4′-selenothymidine triphosphate by taking advantage of its bioequivalence against DNA polymerases.
Collapse
Affiliation(s)
- N. Tarashima
- Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - T. Sumitomo
- Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - H. Ando
- Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - K. Furukawa
- Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - T. Ishida
- Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - N. Minakawa
- Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| |
Collapse
|